The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
July 2022
in “JEADV Clinical Practice”
We don't know much about this study yet.
We're trying to become the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.Cited in this study
research Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study
research Dutasteride intralesional microinjections in combination with oral minoxidil vs. oral minoxidil monotherapy in men with androgenetic alopecia: a retrospective analysis of 105 patients
research Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients
Dutasteride is the most effective hair loss treatment after 24 weeks, but finasteride leads to the most hair growth after 48 weeks.
research Efficacy and safety profile of oral spironolactone use for androgenic alopecia: A systematic review.
research Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia
A new treatment called SAMiRNA-AR68 increases hair count in people with hair loss, showing similar results to existing treatments but without side effects.
research Efficacy of botulinum toxin A injection in the treatment of androgenic alopecia: A Comparative Controlled Study
Botox can effectively treat hair loss with some side effects and high cost, while LC hair serum also shows great results with fewer side effects.
research Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

research Minoxidil: a comprehensive review
Minoxidil effectively treats hair loss, especially androgenetic alopecia, but needs more research for better understanding.

research Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
Low-dose oral minoxidil safely treats hair loss, with hypertrichosis as main side effect.
research Efficacy of Finasteride in Female Pattern Hair Loss: A Meta-Analysis

research Is there a rationale for the use of botulinum toxin in the treatment of Androgenetic Alopecia?
Botulinum toxin may help hair loss by increasing blood flow and reducing harmful factors.

research Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case‐controlled study
Topical cetirizine 1% promotes hair growth in male androgenetic alopecia patients.
research Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study

research Characterization and management of hypertrichosis induced by low-dose oral minoxidil in the treatment of hair loss
Low-dose oral minoxidil for hair loss can cause mild excessive hair growth, usually appearing within the first 3 months, but it can be managed by adjusting the dose or removing the unwanted hair, with most people not needing to stop the treatment.

research The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial
PRP injections improve hair density and thickness in women with hair loss.

research Accelerated hair growth by combining thread monofilament and minoxidil in female androgenetic alopecia
Thread monofilament and minoxidil together increase hair growth in female androgenetic alopecia.

research The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism
Botulinum toxin injections may help treat hair loss by blocking harmful secretion in hair follicles.

research Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss
Bicalutamide may be a promising alternative treatment for female pattern hair loss.

research Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients
Oral bicalutamide is safe and effective for female hair loss.

research Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial
Oral minoxidil and topical minoxidil 5% both effectively improve female-pattern hair loss with safe side effects.

research Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study
Oral dutasteride improves hair growth, reduces hair loss, and is safe for most patients.
research Comparison of efficacy of platelet-rich plasma therapy with or without topical 5% minoxidil in male-type baldness: A randomized, double-blind placebo control trial

research A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia
Clascoterone safely promotes hair growth similar to minoxidil.

research
Minoxidil and its use in hair disorders: a review
Minoxidil effectively treats hair loss, but use cautiously and monitor side effects.

research Efficacy and Safety of a Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Self-Comparison, Sham Device-Controlled Trial
Low-level light therapy safely improves hair coverage, thickness, and count in androgenetic alopecia patients.

research Photobiomodulation therapy for androgenetic alopecia: A clinician’s guide to home-use devices cleared by the Federal Drug Administration
FDA-cleared devices may help treat hair loss, but more research needed; consult dermatologist before use.

research Platelet-rich plasma for androgenetic alopecia: Does it work? Evidence from meta analysis
PRP treatment may increase hair density and reduce hair loss, but more research is needed.

research A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia
PRP treatment may stimulate hair growth by promoting blood vessel formation, increasing growth factors, and preventing cell death.

research The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia
Finasteride and dutasteride effectively stop or reverse hair loss in women with androgenetic alopecia, with dutasteride being more effective for women under 50.

research A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia
Dutasteride 0.5 mg works better than finasteride and placebo for increasing hair in men with hair loss.

research Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation
Dutasteride-containing mesotherapy effectively treats female hair loss, improving density and thickness with minimal side effects.

research Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males
Dutasteride mesotherapy helps treat male hair loss but may harm sperm and sexual function.

research Human hair follicles contain two forms of ATP‐ sensitive potassium channels, only one of which is sensitive to minoxidil
One minoxidil-sensitive potassium channel exists in human hair follicles.

research The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride
Dutasteride more effective for hair growth, but has more side effects than finasteride.

research Pharmacogenetic analysis of human steroid 5α reductase type II: comparison of finasteride and dutasteride
Dutasteride is more efficient than finasteride, but individual results vary.

research Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia
Finasteride doesn't effectively treat hair loss in postmenopausal women.